Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.83 |
| ▸ | USP2 | O75604 | 1/20 | 0.83 |
| ▸ | RECQL | P46063 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086430 | 0.95 | USP2 (0.75) | SMN1; SMN2USP2RECQLMEN1TP53 | |
| SCHEMBL344191 | 0.93 | SMN1; SMN2 (0.96) | SMN1; SMN2USP2RECQLTP53TSHR | |
| SCHEMBL20448044 | 0.91 | SMN1; SMN2 (1.00) | SMN1; SMN2USP2RECQLTP53TSHR | |
| SCHEMBL27388627 | 0.89 | USP2 (0.62) | SMN1; SMN2USP2RECQLMEN1KMT2A | |
| Acetic Acid SCHEMBL29118271 | 0.87 | SMN1; SMN2 (0.86) | SMN1; SMN2USP2RECQLTSHRPOLB | |
| SCHEMBL2920417 | 0.86 | SMN1; SMN2 (0.83) | SMN1; SMN2USP2RECQLMEN1TP53 | |
| SCHEMBL18084793 | 0.84 | SMN1; SMN2 (0.80) | SMN1; SMN2USP2RECQLMEN1TP53 | |
| SCHEMBL28204425 | 0.84 | SMN1; SMN2 (0.80) | SMN1; SMN2USP2RECQLTSHRPOLB | |
| SCHEMBL26129549 | 0.83 | HPGD (0.60) | SMN1; SMN2USP2RECQLMEN1KMT2A | |
| Formic Acid Methyl Ester SCHEMBL29022264 | 0.83 | SMN1; SMN2 (0.77) | SMN1; SMN2USP2RECQLTSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778299-B | Piperazine ureido derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-112778299-A | Piperazine ureido derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2021-05-11 | — | — | CN | disclosed |
| EP-1812445-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-12-30 | — | — | EP | disclosed |
| EP-1812444-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-08-26 | — | — | EP | disclosed |
| US-8946217-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | US | disclosed |
| US-20130317017-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2013-11-28 | — | — | US | disclosed |
| US-20120258966-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-8153629-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-8101607-B2 | Pharmaceutical compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2012-01-24 | — | — | US | disclosed |
| US-7776856-B2 | Pharmaceutical compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2010-08-17 | — | — | US | disclosed |
| US-7750002-B2 | Pharmaceutical compounds | PIRAMED LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| US-20090131429-A1 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20080207611-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1812445-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| EP-1812444-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006046035-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| US-5561140-A | IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-10-01 | — | — | US | disclosed |
| US-5530119-A | IMMUNOSUPPRESSANTS | ABBOTT LABORATORIES (US) | 1996-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | SMN1; SMN2 1242/4885USP2 4409/4885RECQL 311/4885 |
| US-20090131429-A1 | Pharmaceutical compounds | PIK3CA, PIK3C2B, PIK3CD | SMN1; SMN2 2169/4885USP2 4272/4885RECQL 547/4885 |
| US-20080207611-A1 | Pharmaceutical compounds | PIK3CA, JAK2, PIK3R1 | SMN1; SMN2 1238/4885USP2 4410/4885RECQL 316/4885 |
| US-20120258966-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | SMN1; SMN2 1242/4885USP2 4409/4885RECQL 311/4885 |
| US-20130317017-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | SMN1; SMN2 1242/4885USP2 4409/4885RECQL 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.